Editorial: Adiponectin in health and disease: Current evidence and therapeutic perspectives

Current Medicinal Chemistry

Volumn 19, Issue 32, 2012, Pages 5425-5426

  Polyzos, Stergios A ^a  

^a NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CADHERIN; G PROTEIN COUPLED RECEPTOR; ISOPROTEIN; RECOMBINANT CYTOKINE; TOLL LIKE RECEPTOR 4;

ADIPOCYTE; AUTOIMMUNE DISEASE; CACHEXIA; CARDIOVASCULAR DISEASE; CONNECTIVE TISSUE DISEASE; CRITICAL ILLNESS; CYTOKINE RELEASE; DIETARY INTAKE; EDITORIAL; ETHNICITY; EXERCISE; GENDER; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIFESTYLE MODIFICATION; LIVER CLEARANCE; LIVER PROTECTION; METABOLIC BONE DISEASE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84870466540     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833191     Document Type: Editorial

References (24)

1. Hickman, I.J.; Whitehead, J.P. Structure, signalling and physiologic role of adiponectin - dietary and exercise-related variations. Curr. Med. Chem., 2012, 19(32), 5427-5443.
2. Retnakaran, A.; Retnakaran, R. Adiponectin in Pregnancy: Implications for Health and Disease. Curr. Med. Chem., 2012, 19(32), 5444-5450.
3. Xita, N.; Tsatsoulis, A. Adiponectin in diabetes mellitus. Curr. Med. Chem., 2012, 19(32), 5451-5458.
4. Shibata, R.; Murohara, T.; Ouchi, N. Adiponectin in cardiovascular disease. Curr. Med. Chem., 2012, 19(32), 5459-5466.
5. Moschen, A.R.; Wieser, V.; Tilg, H. Adiponectin: Key Player in the Adipose Tissue-Liver Crosstalk. Curr. Med. Chem., 2012, 19(32), 5467-5473.
6. Kanazawa, I. Adiponectin in metabolic bone disease. Curr. Med. Chem., 2012, 19(32), 5474-5480.
7. Toussirot, E.; Binda, D.; Gueugnon, C.; Dumoulin, G. Adiponectin in autoimmune diseases. Curr. Med. Chem., 2012, 19(32), 5481-5492.
8. Garcia, P.; Sood, A. Adiponectin in pulmonary disease and critically ill patients. Curr. Med. Chem., 2012, 19(32), 5493-5500.
9. Perrier, S.; Jarde, T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr. Med. Chem., 2012, 19(32), 5501-5512.
10. Li.F.Y.L.; Lam, K.S.L.; Xu, A. Therapeutic perspectives for adiponectin: an update. Curr. Med. Chem., 2012, 19(32), 5513-5523.
11. Polyzos, S.A.; Kountouras, J.; Zavos, C.; Tsiaousi, E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes. Metab., 2010, 12, 365-383.
12. Polyzos, S.A.; Kountouras, J.; Zavos, C. Non-linear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. J. Clin. Gastroenterol., 2010, 44, 229-230.
13. Attanasio, P.; Anker, S.D.; Doehner, W.; von, H.S. Hormonal consequences and prognosis of chronic heart failure. Curr. Opin. Endocrinol. Diabetes Obes., 2011, 18, 224-230.
14. Krysiak, R.; Handzlik-Orlik, G.; Okopien, B. The role of adipokines in connective tissue diseases. Eur. J. Nutr., 2012, (epub ahead of print).
15. Miehle, K.; Stepan, H.; Fasshauer, M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin. Endocrinol. (Oxf.), 2012, 76, 2-11.
16. Beige, J.; Heipmann, K.; Stumvoll, M.; Korner, A.; Kratzsch, J. Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology. Expert. Opin. Ther. Targets, 2009, 13, 163-173.
17. Walkey, A.J.; Rice, T.W.; Konter, J.; Ouchi, N.; Shibata, R.; Walsh, K.; deBoisblanc, B.P.; Summer, R. Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit. Care Med., 2010, 38, 2329-2334.
18. Maiolino, G.; Cesari, M.; Sticchi, D.; Zanchetta, M.; Pedon, L.; Antezza, K.; Pessina, A.C.; Rossi, G.P. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J. Clin. Endocrinol. Metab., 2008, 93, 3333-3340.
19. Polyzos, S.A.; Toulis, K.A.; Goulis, D.G.; Zavos, C.; Kountouras, J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism, 2011, 60, 313-326.
20. Polyzos, S.A.; Kountouras, J.; Zavos, C.; Stergiopoulos C Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: The two sides of the same coin. Med. Hypotheses, 2010, 74, 1089-1090.
21. Larter, C.Z.; Yeh, M.M.; Williams, J.; Bell-Anderson, K.S.; Farrell, G.C. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J. Hepatol., 2008, 49, 407-416.
22. Van Berendoncks, A.M.; Conraads, V.M. Functional adiponectin resistance and exercise intolerance in heart failure. Curr. Heart Fail. Rep., 2011, 8, 113-122.
23. Polyzos, S.A.; Kountouras, J.; Zavos, C. Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas. Int. J. Clin. Pract., 2011, 65, 373-374.
24. Polyzos, S.A.; Kountouras, J.; Zavos, C. Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol. Res., 2010, 40, 446-447.